Heron Therapeutics, Inc.HRTXNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
-16.51%
↓ 164% below average
Average (39q)
25.80%
Historical baseline
Range
High:509.21%
Low:-69.56%
CAGR
+0.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -16.51% |
| Q2 2025 | -10.19% |
| Q1 2025 | -0.35% |
| Q4 2024 | 30.84% |
| Q3 2024 | -8.45% |
| Q2 2024 | -2.75% |
| Q1 2024 | 7.71% |
| Q4 2023 | 84.09% |
| Q3 2023 | 13.98% |
| Q2 2023 | -9.07% |
| Q1 2023 | -26.67% |
| Q4 2022 | 46.97% |
| Q3 2022 | 3.36% |
| Q2 2022 | -5.35% |
| Q1 2022 | 24.58% |
| Q4 2021 | -18.23% |
| Q3 2021 | 49.97% |
| Q2 2021 | -26.73% |
| Q1 2021 | -3.59% |
| Q4 2020 | -12.36% |
| Q3 2020 | -6.35% |
| Q2 2020 | -7.54% |
| Q1 2020 | -23.07% |
| Q4 2019 | -24.46% |
| Q3 2019 | 10.22% |
| Q2 2019 | 38.65% |
| Q1 2019 | -3.66% |
| Q4 2018 | 41.46% |
| Q3 2018 | 1.36% |
| Q2 2018 | 42.83% |
| Q1 2018 | -3.22% |
| Q4 2017 | 15.88% |
| Q3 2017 | 0.32% |
| Q2 2017 | 206.50% |
| Q1 2017 | 96.62% |
| Q4 2016 | 509.21% |
| Q3 2016 | 98.89% |
| Q2 2016 | -69.56% |
| Q1 2016 | 1.05% |
| Q4 2015 | -14.20% |